Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001209191-23-059715)

Filing Details

Accession Number:: 0001209191-23-059715
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-12-26 19:29:13
Reporting Period:: 2023-12-21

Accepted Time:: 2023-12-26 19:29:13
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1672619	Enliven Therapeutics Inc.	ELVN	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1584759	A. Richard Heyman	C/O Enliven Therapeutics, Inc. 6200 Lookout Road Boulder CO 80301		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-12-21	7	$13.00	147,448	No	4	S	Direct
Common Stock	Disposition	2023-12-21	6	$13.00	29,251	No	4	S	Indirect	See footnote
Common Stock	Disposition	2023-12-22	168	$13.00	147,280	No	4	S	Direct
Common Stock	Disposition	2023-12-22	35	$13.00	29,216	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Indirect	See footnote
No	4	S	Direct
No	4	S	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	37,407	Indirect	See footnote

Footnotes

The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023.
The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member.
The shares are held of record by the Richard A. Heyman and Anne E. Daigle Trust, dated November 1, 2016 for which the Reporting Person serves as trustee.